Page 56 - Human Use News Today

The European Commission has approved piflufolastat (18F) for the detection of prostate-specific membrane antigen–positive lesions with positron emission tomography in adults with prostate cancer.

Paris, France: 27 July 2023Ipsen , a global specialty-care biopharmaceutical company, presents today its financial results for the first half of 2023. H1 2023 total sales up by 7.4% at CER1 , with...

Reports Second Quarter Revenues of $11.2 Billion Posts Second Quarter GAAP Earnings Per Share of $0.99 and Non-GAAP EPS of $1.75; Includes Net Impact of Per Share for GAAP and Non-GAAP EPS Due...

Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of...

/PRNewswire/ -- According to Prophecy Market Insights "Enzyme Replacement Therapy Market accounted for US$ 8.28 billion in 2020 and is estimated to be US$...

M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Such...

NEW YORK, July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc.  . Such investors are advised to contact Robert S. Willoughby...

By Anthony O. Goriainoff GSK said Monday that its HIV prevention treatment cabotegravir has been recommended for marketing authorization in the European Union. The London-listed...

GSK ViiV Healthcare welcome positive opinion by EMA for cabotegravir